---
title: "SMA Newborn Screening Kits"
ocid: "ocds-r6ebe6-0000826401"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000826401"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000826401.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000826401.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "NHS GREATER GLASGOW AND CLYDE"
published: "2026-04-02"
---

# SMA Newborn Screening Kits

Buyer: NHS GREATER GLASGOW AND CLYDE  
Current stage: Award  
OCID: ocds-r6ebe6-0000826401

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000826401)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000826401.json)

## Summary

The contracting process for the procurement of SMA Newborn Screening Kits has been completed by NHS Greater Glasgow and Clyde. This procurement falls under the health industry category, specifically focusing on genetic screening for Spinal Muscular Atrophy (SMA) in newborns. The contract, valued at £237,847, was awarded to Labsystems Diagnostics OY, a supplier recognised for its specialised screening kits. Key details include the procurement method, which involved a limited procedure without prior publication due to the absence of competition for technical reasons as established by Regulation 33. The contract was signed on 5th March 2026, with the screening required to comply with the Scottish screening protocol, thereby providing significant health benefits to the local population in the Glasgow region (UKM82).

This tender represents an opportunity for businesses specialising in medical diagnostics and genetic screening to explore potential collaborations with NHS Greater Glasgow and Clyde. Companies that can provide innovative screening technologies conforming to regional protocols, specifically those involving gene measurement like SMN1 and SMN2, are well-positioned to compete for related contracts. Such businesses, particularly SMEs and those operating within the EU, could benefit from forging relationships with public health bodies and contribute to advancements in genetic diagnostics, thereby enhancing their portfolio and market positioning in the healthcare sector.

## Notice

The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).

### Lot Information

Lot 1

The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). Scotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel. SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2. SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.

### Procurement Information

In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217 |
| Notice type | OJEU - F3 - Contract Award Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 2 Apr 2026 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 5 Mar 2026 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £237,847 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS GREATER GLASGOW AND CLYDE |
| Locality | GLASGOW |
| Post town | Glasgow |
| Postcode | G4 0SF |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM3 West Central Scotland |
| ITL 3 | TLM32 Glasgow City |
| Local authority | Glasgow City |
| Electoral ward | Dennistoun |
| Westminster constituency | Glasgow North East |
| Delivery location | TLM82 Glasgow City |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | LABSYSTEMS DIAGNOSTICS |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33696500 - Laboratory reagents

## Release History

- 2 Apr 2026 at 00:00 - Award - OJEU - F3 - Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
- 19 Mar 2026 at 00:00 - Award - OJEU - F15 - Voluntary Ex Ante Transparency Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048
  SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
  SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).

## Notice URLs

- http://
- http://www.nhsggc.scot/about-us/procurement/
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000826401. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000826401.json.